Brief: Verastem Oncology Announces Encouraging Preliminary Data From Ongoing Phase 1/2A Dose Escalation Trial Of Versus-7375, An Oral Kras G12d (On/Off) Inhibitor, In Patients With Kras G12d Mutant Solid Tumors
23/10/2025 23:37
Oct 24 (Reuters) - Verastem Inc VSTM.O: VERASTEM ONCOLOGY ANNOUNCES ENCOURAGING PRELIMINARY DATA FROM ONGOING PHASE 1/2A DOSE ESCALATION TRIAL OF VERSUS-7375, AN ORAL KRAS G12D (ON/OFF) INHIBITOR, IN PATIENTS WITH KRAS G12D MUTANT SOLID TUMORS VERASTEM INC - FIRST TWO DOSE LEVELS CLEARED WITH NO DOSE-LIMITING TOXICITIES VERASTEM INC - PROMISING ANTI-TUMOR ACTIVITY OBSERVED IN SOLID TUMORS VERASTEM INC - INTERIM SAFETY AND EFFICACY UPDATE PLANNED FOR FIRST HALF OF 2026 Source text: ID:nBw3zP2Xna Further company coverage: VSTM.O ((Reuters.Briefs@thomsonreuters.com;))